

Attend these presentations during the 63rd ASH annual meeting to see how NGS is advancing hemato-oncology studies.

Immune repertoire analysis of multiple myeloma research samples using NGS characterization of multiple B cell receptors in a single reaction

Number: 1881

Presenter: Geoffrey Lowman

Session: 803. Emerging diagnostic tools and techniques: Poster I

Time and location: Saturday, December 11, 2021
5:30–7:30 p.m., Hall B5 (Georgia World Congress Center)

Genetic landscape and clonal evolution patterns of CEBPA-mutated acute myeloid leukemia based on next-generation sequencing: a retrospective analysis

Number: 2363

Presenter: Livia Leuzzi

Session: 617. Acute myeloid leukemias: biomarkers, molecular markers, and minimal residual disease in diagnosis and prognosis: Poster II

Time and location: Sunday, December 12, 2021
6:00–8:00 p.m., Hall B5 (Georgia World Congress Center)

Spectrum of myeloid mutations in patients with elevated hemoglobin

Number: 2577

Presenter: Pratibha Bhai

Session: 634. Myeloproliferative syndromes: clinical and epidemiological: Poster III

Time and location: Sunday, December 12, 2021
6:00–8:00 p.m., Hall B5 (Georgia World Congress Center)



Fully automated workflows quantify and report key T cell and B cell receptor biomarkers relevant to immuno-oncology and heme-oncology research

Number: 4002

Presenter: Shrutii Sarda

Session: 803. Emerging diagnostic tools and techniques: Poster III

Time and location: Monday, December 13, 2021
6:00–8:00 p.m., Hall B5 (Georgia World Congress Center)

SEL24/MEN1703 inhibits PIM/FLT3 downstream target in acute myeloid leukemia (AML) patients: results of the pharmacodynamics (PD) assay and genomic profiling in the first-in-human DIAMOND-01 trial

Number: 3436

Presenter: Alessandro Paoli

Session: 617. Acute myeloid leukemias: biomarkers, molecular markers, and minimal residual disease in diagnosis and prognosis: Poster III

Time and location: Monday, December 13, 2021
6:00–8:00 p.m., Hall B5 (Georgia World Congress Center)

Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: interim analysis of a prospective, multicenter, single-arm, phase 2 trial

Number: 35

Presenter: Suning Chen

Session: 615. Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: innovative induction regimens in AML: data from real life and clinical trials

Time and location: Saturday, December 11, 2021
9:30–11:00 a.m., B405–B407 (Georgia World Congress Center)

Learn more and download our posters at oncomine.com/ash2021

ion torrent